Your browser doesn't support javascript.
loading
Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia.
Wedenoja, Satu; Yoshihara, Masahito; Teder, Hindrek; Sariola, Hannu; Gissler, Mika; Katayama, Shintaro; Wedenoja, Juho; Häkkinen, Inka M; Ezer, Sini; Linder, Nina; Lundin, Johan; Skoog, Tiina; Sahlin, Ellika; Iwarsson, Erik; Pettersson, Karin; Kajantie, Eero; Mokkonen, Mikael; Heinonen, Seppo; Laivuori, Hannele; Krjutskov, Kaarel; Kere, Juha.
Afiliação
  • Wedenoja S; Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; Stem Cells and Metabolism Research Program, University of Helsinki, and Folkhälsan Research Center, 00290 Helsinki, Finland. Electronic address: satu.wedenoja@helsinki.fi.
  • Yoshihara M; Department of Biosciences and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden.
  • Teder H; Competence Centre of Health Technologies, 50411 Tartu, Estonia; Institute of Biomedicine and Translational Medicine, University of Tartu, 50090 Tartu, Estonia.
  • Sariola H; University of Helsinki and HUSLAB Pediatric Pathology, 00290 Helsinki, Finland.
  • Gissler M; Information Services Department, Finnish Institute for Health and Welfare, 00300 Helsinki, Finland; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 17177 Stockholm, Sweden; Research Centre for Child Psychiatry, University of Turku, 20500 Turku, Finland.
  • Katayama S; Stem Cells and Metabolism Research Program, University of Helsinki, and Folkhälsan Research Center, 00290 Helsinki, Finland; Department of Biosciences and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden.
  • Wedenoja J; Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
  • Häkkinen IM; Stem Cells and Metabolism Research Program, University of Helsinki, and Folkhälsan Research Center, 00290 Helsinki, Finland.
  • Ezer S; Stem Cells and Metabolism Research Program, University of Helsinki, and Folkhälsan Research Center, 00290 Helsinki, Finland.
  • Linder N; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland; Department of Women's and Children's Health, International Maternal and Child Health, Uppsala University, 75105 Uppsala, Sweden.
  • Lundin J; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland; Department of Public Health Sciences, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Skoog T; Department of Biosciences and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden.
  • Sahlin E; Department of Molecular Medicine and Surgery, Karolinska Institutet, and Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Iwarsson E; Department of Molecular Medicine and Surgery, Karolinska Institutet, and Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Pettersson K; Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, and Department of Obstetrics, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Kajantie E; Public Health Promotion Unit, Finnish Institute for Health and Welfare, 00300 Helsinki and 90220 Oulu, Finland; PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, 90570 Oulu, Finland; Department of Clinical and Molecular Medicine, Norwegian University of Science and Tec
  • Mokkonen M; Department of Biology, Kwantlen Polytechnic University, Surrey, BC V3W 2M8, Canada; Department of Biological Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
  • Heinonen S; Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
  • Laivuori H; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland; Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; Department of Obstetrics and Gynecology, Tampere University
  • Krjutskov K; Stem Cells and Metabolism Research Program, University of Helsinki, and Folkhälsan Research Center, 00290 Helsinki, Finland; Department of Biosciences and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden; Competence Centre of Health Technologies, 50411 Tartu, Estonia.
  • Kere J; Stem Cells and Metabolism Research Program, University of Helsinki, and Folkhälsan Research Center, 00290 Helsinki, Finland; Department of Biosciences and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden. Electronic address: juha.kere@ki.se.
EBioMedicine ; 59: 102872, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32680723
ABSTRACT

BACKGROUND:

Fetal immune tolerance is crucial for pregnancy success. We studied the link between preeclampsia, a severe pregnancy disorder with uncertain pathogenesis, and fetal human leukocyte antigen G (HLA-G) and other genes regulating maternal immune responses.

METHODS:

We assessed sex ratios and regulatory HLA-G haplotypes in population cohorts and series of preeclampsia and stillbirth. We studied placental mRNA expression of 136 genes by sequencing and HLA-G and interferon alpha (IFNα) protein expression by immunohistochemistry.

FINDINGS:

We found underrepresentation of males in preeclamptic births, especially those delivered preterm or small for gestational age. Balancing selection at HLA-G associated with the sex ratio, stillbirth, and preeclampsia. We observed downregulation of HLA-G, its receptors, and many other tolerogenic genes, and marked upregulation of IFNA1 in preeclamptic placentas.

INTERPRETATION:

These findings indicate that an evolutionary trade-off between immune tolerance and protection against infections at the maternal-fetal interface promotes genetic diversity in fetal HLA-G, thereby affecting survival, preeclampsia, and sex ratio. We highlight IFNA1 as a potential mediator of preeclampsia and a target for therapeutic trials.

FUNDING:

Finnish Medical Foundation, Päivikki and Sakari Sohlberg Foundation, Karolinska Institutet Research Foundation, Scandinavia-Japan Sasakawa Foundation, Japan Eye Bank Association, Astellas Foundation for Research on Metabolic Disorders, Japan Society for the Promotion of Science, Knut and Alice Wallenberg Foundation, Swedish Research Council, Medical Society Liv och Hälsa, Sigrid Jusélius Foundation, Helsinki University Hospital and University of Helsinki, Jane and Aatos Erkko Foundation, Academy of Finland, Finska Läkaresällskapet, Novo Nordisk Foundation, Finnish Foundation for Pediatric Research, and Emil Aaltonen Foundation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pré-Eclâmpsia / Interferons / Antígenos HLA-G / Tolerância Imunológica / Troca Materno-Fetal Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pré-Eclâmpsia / Interferons / Antígenos HLA-G / Tolerância Imunológica / Troca Materno-Fetal Idioma: En Ano de publicação: 2020 Tipo de documento: Article